Stephens & Co. Maintains Overweight on Guardant Health, Raises Price Target to $195

Benzinga Newsdesk www.benzinga.com Positive 78.3%

Neg 0% Neu 0% Pos 78.3%

Stephens & Co. analyst Mason Carrico maintains Guardant Health (NASDAQ:GH) with a Overweight and raises the price target from $170 to $195.